{"id":"CHEMBL1078685","canonicalSmiles":"N#Cc1cc(-c2n[nH]c(-c3ccncc3)n2)ccn1","inchiKey":"UBVZQGOVTLIHLH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TOPIROXOSTAT","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["FYX-051","Topiroxostat"],"crossReferences":{"drugbank":["DB01685"]},"linkedTargets":{"rows":["ENSG00000158125"],"count":1},"linkedDiseases":{"rows":["EFO_0009104","EFO_0000401"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1162","canonicalSmiles":"C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C","inchiKey":"VIKNJXKGJWUCNN-XGXHKTLJSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"NORETHINDRONE","yearOfFirstApproval":1962,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aygestin","Camila","Errin","Heather","Incassia","Jencycla","Menzol","Micronor","Micronor hrt","Nor-qd","Norethidrone","Norethindrone","Noriday","Norlutin","Primolut n","Utovlan"],"synonyms":["Activella","Anovule","Aygestin","Calluna vulgaris","Calluna vulgaris whole","Combipatch","Femhrt","Gestest","Heather whole","NSC-9564","Norethindrone","Norethisteron","Norethisterone","Norethisteronum","Norlutate","SC-4640","Triella"],"crossReferences":{"DailyMed":["norethindrone"],"PubChem":["144204875","144212744","170464683","49647479"],"Wikipedia":["Norethisterone"],"drugbank":["DB00717"],"chEBI":["7627"]},"linkedTargets":{"rows":["ENSG00000082175"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0002687","EFO_0001065","EFO_0009006","EFO_0007453","EFO_0003929","Orphanet_1195","EFO_0003843","EFO_0000311","EFO_0004714","EFO_0008520","HP_0100607","EFO_0003047","EFO_0008522","EFO_0003922"],"count":15},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1962 and has 13 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1190262","canonicalSmiles":"CCCCCCCC/N=C(N)/N=C(\\N)NCc1ccc(Cl)c(Cl)c1","inchiKey":"ZZQMUJGZCZTLQD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OLANEXIDINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Olanexidine"],"childChemblIds":["CHEMBL540531","CHEMBL3989554"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1200410","canonicalSmiles":"CNNCc1ccc(C(=O)NC(C)C)cc1.Cl","inchiKey":"DERJYEZSLHIUKF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"PROCARBAZINE HYDROCHLORIDE","yearOfFirstApproval":1969,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1321","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Matulane","Natulan"],"synonyms":["Ibenzmethyzine hydrochloride","NCI-C 01810","NCI-C-01810","NSC-77213","Procarbazine hcl","Procarbazine hydrochloride","Procarbazini hydrochloridum","RO 4-646711","RO-4-6467 HYDROCHLORIDE","Ro-46467/1"],"crossReferences":{"DailyMed":["procarbazine%20hydrochloride"],"PubChem":["144203990","144212635","170465402","49681829","551000"],"chEBI":["71428"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1969 and has 6 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1200434","canonicalSmiles":"C[N+](C)(C)CCO.Cn1c(=O)c2[n-]cnc2n(C)c1=O","inchiKey":"RLANKEDHRWMNRO-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"OXTRIPHYLLINE","yearOfFirstApproval":1981,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL190","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Choledyl","Choledyl sa","Oxtriphylline","Oxtriphylline pediatric","Sabidal"],"synonyms":["Choline theophyllinate","Choline theophylline","Cholinophyllin","NSC-760431","Oxtriphylline","Theocolin"],"crossReferences":{"DrugCentral":["4390"],"Wikipedia":["Choline_theophyllinate"],"drugbank":["DB01303"]},"linkedTargets":{"rows":["ENSG00000152270","ENSG00000282608","ENSG00000065989","ENSG00000128271","ENSG00000163485","ENSG00000170425","ENSG00000105650","ENSG00000113448","ENSG00000172572","ENSG00000184588"],"count":10},"linkedDiseases":{"rows":["HP_0006536"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1981 and is indicated for airway obstruction."}
{"id":"CHEMBL1200438","canonicalSmiles":"Clc1ccc(C(Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1","inchiKey":"QXHHHPZILQDDPS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TIOCONAZOLE","yearOfFirstApproval":1983,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Tioconazole","Trosyl","Tz-3","Vagistat","Vagistat-1"],"synonyms":["NSC-759169","Tioconazole","UK-20,349","UK-20349"],"crossReferences":{"PubChem":["144205987","170465343","50112684"],"Wikipedia":["Tioconazole"],"drugbank":["DB01007"],"chEBI":["77898"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1983."}
{"id":"CHEMBL1200453","canonicalSmiles":"CCCCCCCCCCCCCCCCCCCCCCO","inchiKey":"NOPFSRXAKWQILS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DOCOSANOL","yearOfFirstApproval":2000,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Abreva"],"synonyms":["Behenic alcohol","Behenyl alcohol","Docosanol","Lidakol","N-docosanol","NSC-8407","Stenol 1822"],"crossReferences":{"DailyMed":["docosanol"],"PubChem":["174006877","29215293"],"Wikipedia":["Docosanol"],"drugbank":["DB00632"],"chEBI":["31000"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for viral disease and has 1 investigational indication."}
{"id":"CHEMBL1200470","canonicalSmiles":"COc1ccc2[n-]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.[Na+]","inchiKey":"RYXPMWYHEBGTRV-JIDHJSLPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ESOMEPRAZOLE SODIUM","yearOfFirstApproval":2005,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201320","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Esomeprazole sodium","Nexium","Nexium iv"],"synonyms":["Esomeprazole (as sodium)","Esomeprazole sodium","H199/18 SODIUM"],"crossReferences":{"DailyMed":["esomeprazole%20sodium"]},"linkedTargets":{"rows":["ENSG00000105675"],"count":1},"linkedDiseases":{"rows":["EFO_0003948","EFO_0009454","MONDO_0004247","EFO_0004607","EFO_1000961"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for duodenal ulcer and gastroesophageal reflux disease and has 1 investigational indication."}
{"id":"CHEMBL1200599","canonicalSmiles":"Cl.N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1","inchiKey":"VMIZTXDGZPTKIK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIFENOXIN HYDROCHLORIDE","yearOfFirstApproval":1978,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201321","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Difenoxin hcl","Difenoxin hydrochloride","Difenoxine hydrochloride","R 15,403","R-15403"],"crossReferences":{"DailyMed":["difenoxin%20hydrochloride"],"chEBI":["59790"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1978."}
{"id":"CHEMBL1200877","canonicalSmiles":"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C","inchiKey":"JWRMHDSINXPDHB-OJAGFMMFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLUMETHASONE PIVALATE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Locorten","Locorten-vioform"],"synonyms":["Flumetasone pivalate","Flumethasone 21-pivalate","Flumethasone pivalate","NSC-107680"],"crossReferences":{"PubChem":["56423133","855730"],"chEBI":["31620"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."}
{"id":"CHEMBL1201006","canonicalSmiles":"COc1ccc(CN(CCN(C)C)c2ccccn2)cc1.O=C(O)/C=C\\C(=O)O","inchiKey":"JXYWFNAQESKDNC-BTJKTKAUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PYRILAMINE MALEATE","yearOfFirstApproval":1973,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL511","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Pyrilamine maleate"],"synonyms":["Antamine","Anthisan","Dorantamin","Enrumay","Histalon","Histan","Histapyran","Histatex","Mepyramine maleate","NSC-3604","Neo-antergan","Paraminyl","Parmal","Pyramal","Pyrilamine maleate","Stamine","Stangen","Thylogen"],"crossReferences":{"PubChem":["144207712","26747601","26747602","50106737","50106738","50106739","56422415","855902","93576628"]},"linkedTargets":{"rows":["ENSG00000196639"],"count":1},"linkedDiseases":{"rows":["EFO_0003956"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1973 and is indicated for seasonal allergic rhinitis."}
{"id":"CHEMBL1201227","canonicalSmiles":"OC(CCN1CCCCC1)(c1ccccc1)C1CCCC1","inchiKey":"SWRUZBWLEWHWRI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CYCRIMINE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Cycrimine"],"crossReferences":{"Wikipedia":["Cycrimine"],"drugbank":["DB00942"],"chEBI":["59692"]},"childChemblIds":["CHEMBL1200828"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."}
{"id":"CHEMBL1201355","canonicalSmiles":"CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)[C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O","inchiKey":"YRALAIOMGQZKOW-HYAOXDFASA-N","drugType":"Protein","blackBoxWarning":false,"name":"CERULETIDE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Caerulein","Cerulein","Ceruletide"],"crossReferences":{"Wikipedia":["Ceruletide"],"drugbank":["DB00403"],"chEBI":["59219"]},"childChemblIds":["CHEMBL1200755"],"description":"Protein drug with a maximum clinical trial phase of IV that was first approved in 1982."}
{"id":"CHEMBL1201580","drugType":"Antibody","blackBoxWarning":true,"name":"ADALIMUMAB","yearOfFirstApproval":2002,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Humira"],"synonyms":["AVT-02","Abp-501","Abrilada","Adalimumab","Adalimumab (genetical recombination)","Adalimumab (humira)","Adalimumab beta","Adalimumab biosimilar (alvotech)","Adalimumab biosimilar (avt02)","Adalimumab biosimilar (ct-p17)","Adalimumab biosimilar (fkb-327)","Adalimumab biosimilar (zrc-3197)","Adalimumab-adaz","Adalimumab-adbm","Adalimumab-afzb","Adalimumab-atto","Adalimumab-bwwd","Adalimumab-fkjp","Amjevita","Avt02","BI695501","Bcd-057","Bi-695501","CT-P17","Chs-1420","Cyltezo","D2E7","Exemptia","FKB-327","FKB327","GP2017","Gp-2017","HLX-03","HLX03","Hadlima","Hulio","Hyrimoz","LU-200134","LU200134","M-923","M923","MSB-11022","MSB11022","Ons-3010","Trudexa","ZRC-3197","ZRC3197"],"crossReferences":{"DailyMed":["adalimumab"],"DrugCentral":["4904"],"Wikipedia":["Adalimumab"]},"linkedTargets":{"rows":["ENSG00000232810"],"count":1},"linkedDiseases":{"rows":["EFO_0000729","EFO_0004683","EFO_1000710","EFO_0003780","EFO_0008507","EFO_0003778","EFO_0000540","HP_0011868","Orphanet_634","Orphanet_247353","EFO_0000676","EFO_0004616","HP_0000999","Orphanet_583","EFO_1000789","Orphanet_797","EFO_0000685","EFO_1000811","EFO_1001857","EFO_0005856","MONDO_0002108","EFO_0003898","EFO_0004236","EFO_0000384","EFO_0002609","EFO_0004229","EFO_1001209","EFO_1001231","MP_0001845","MONDO_0100096","MONDO_0004979","EFO_0000706","MONDO_0005178","EFO_0003767","EFO_0003872"],"count":35},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 7 approved and 23 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1201636","drugType":"Enzyme","blackBoxWarning":false,"name":"HYALURONIDASE","yearOfFirstApproval":2004,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Amphadase","Hyalase","Hydase","Jalovis","Kinetin","Vitrase","Wydase"],"synonyms":["Hyaluronidase","Hyaluronidase (bovine)","Hyaluronidase bovine","Hyaluronidase, bovine","Hyaluronidases","Hyaluronoglucosaminidase"],"crossReferences":{"DailyMed":["hyaluronidase","hyaluronidase-fihj","hyaluronidase-oysk","hyaluronidase-zzxf"],"DrugCentral":["5033"],"Wikipedia":["Hyaluronidase"]},"description":"Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 15 investigational indications."}
{"id":"CHEMBL1230795","canonicalSmiles":"Nc1ncnc2c1nc(Br)n2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O","inchiKey":"KVVVTFSHHQCHNZ-UUOKFMHZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"8-Bromo-Adenosine Diphosphate","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["8-Bromo-Adenosine Diphosphate"],"crossReferences":{"drugbank":["DB04554"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1231160","canonicalSmiles":"NS(=O)(=O)OC[C@@H]1C[C@@H](n2ccc3c(N[C@H]4CCc5ccccc54)ncnc32)C[C@@H]1O","inchiKey":"MPUQHZXIXSTTDU-QXGSTGNESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PEVONEDISTAT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MLN 4924","MLN-4924","MLN-4924003","MLN4924","Pevonedistat"],"crossReferences":{"drugbank":["DB11759"]},"childChemblIds":["CHEMBL2364622"],"linkedTargets":{"rows":["ENSG00000144744","ENSG00000159593"],"count":2},"linkedDiseases":{"rows":["EFO_0000198","EFO_0000616","EFO_1001779","EFO_0000220","MONDO_0019457","EFO_0000403","EFO_0000222","EFO_0003060","EFO_0000311","EFO_1001961","EFO_0000588","EFO_0000182","EFO_0001378","EFO_0002617"],"count":14},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications."}
{"id":"CHEMBL123368","canonicalSmiles":"NS(=O)(=O)c1cccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)c1","inchiKey":"BKDUVKJYBJDZQW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL123368","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08248"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1233797","canonicalSmiles":"COc1ccc2c(c1)CN(C(=O)CCN1CCC(Cc3ccccc3)CC1)CCS2","inchiKey":"KCWGETCFOVJEPI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1233797","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02929"]},"childChemblIds":["CHEMBL2440857"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1233985","canonicalSmiles":"Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C)c2cc1C","inchiKey":"KPDQZGKJTJRBGU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LUMIFLAVIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Lumiflavin"],"crossReferences":{"drugbank":["DB04726"],"chEBI":["43661"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1235743","canonicalSmiles":"c1ccc([C@@H]2CO2)cc1","inchiKey":"AWMVMTVKBNGEAK-QMMMGPOBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1235743","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["47193692"],"drugbank":["DB04499"],"chEBI":["45389"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1256978","canonicalSmiles":"Cn1c(=O)c(C(=O)NCCO)c(O)c2ncc(Cc3ccc(F)cc3)cc21","inchiKey":"QWLNINWUBHHOLU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GSK-364735","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GSK364735","Gsk-364735","S-364735"],"crossReferences":{"drugbank":["DB13119"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1277072","canonicalSmiles":"Cc1c(/C=C2\\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2","inchiKey":"MCTXSDCWFQAGFS-UEXNTNOUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HENATINIB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Henatinib"],"crossReferences":{"drugbank":["DB13019"]},"linkedTargets":{"rows":["ENSG00000128052"],"count":1},"linkedDiseases":{"rows":["EFO_0000311"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1290","canonicalSmiles":"CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1","inchiKey":"KQXKVJAGOJTNJS-HNNXBMFYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PENBUTOLOL","yearOfFirstApproval":1987,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Levatol","Penbutolol"],"crossReferences":{"Wikipedia":["Penbutolol"],"drugbank":["DB01359"],"chEBI":["7954"]},"childChemblIds":["CHEMBL1200363","CHEMBL2361370"],"linkedTargets":{"rows":["ENSG00000169252","ENSG00000043591"],"count":2},"linkedDiseases":{"rows":["EFO_0000319"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987 and is indicated for cardiovascular disease."}
{"id":"CHEMBL1366933","canonicalSmiles":"CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1","inchiKey":"RONZAEMNMFQXRA-MRXNPFEDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ESMIRTAZAPINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(s)-6-azamianserin","(s)-mirtazapine","(s)-org 3770","Esmirtazapine","Mirtazapine, (s)-","ORG-44-20"],"crossReferences":{"PubChem":["11114267"],"drugbank":["DB06678"]},"childChemblIds":["CHEMBL2107339"],"linkedTargets":{"rows":["ENSG00000184160","ENSG00000274286","ENSG00000102468","ENSG00000196639","ENSG00000150594","ENSG00000147246"],"count":6},"linkedDiseases":{"rows":["EFO_0004698"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 1 investigational indication."}
{"id":"CHEMBL1464","canonicalSmiles":"CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O","inchiKey":"PJVWKTKQMONHTI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"WARFARIN","yearOfFirstApproval":1954,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["NSC-59813","Warfarin"],"crossReferences":{"DailyMed":["warfarin%20sodium"],"PubChem":["144206736","144209380","144210849","174006926","26748308","26754489"],"Wikipedia":["Warfarin"],"drugbank":["DB00682"],"chEBI":["87732"]},"childChemblIds":["CHEMBL1200879","CHEMBL1200772"],"linkedTargets":{"rows":["ENSG00000167397"],"count":1},"linkedDiseases":{"rows":["EFO_0000729","EFO_0003777","EFO_0001361","HP_0002239","EFO_0007401","EFO_0000275","MONDO_0002009","EFO_0000266","EFO_0003914","HP_0001871","EFO_0009952","EFO_0000676","EFO_0000400","EFO_1000059","EFO_0002618","EFO_0002689","MONDO_0005149","EFO_0006911","EFO_0001642","EFO_0004286","HP_0001873","MONDO_0008315","EFO_0000384","EFO_0004239","MP_0001914","EFO_0001422","MONDO_0000831","EFO_0009557","EFO_0000574","EFO_0003907","EFO_0005672","HP_0004418","HP_0000726","EFO_0000768","MONDO_0002679","EFO_1001249","EFO_0000274","EFO_0002950","EFO_0004211","EFO_0003911","EFO_0000474","Orphanet_325","EFO_1001375","EFO_0003144","EFO_0000712","MONDO_0005180","EFO_1001161","HP_0004419","HP_0004936","EFO_0000616","EFO_0000685","HP_0002140","EFO_0003875","EFO_0001645","HP_0001655","EFO_0003929","EFO_0000319","EFO_0004277","EFO_0000311","HP_0001907","MONDO_0001134","EFO_0003764","EFO_0010680","EFO_0003827","MONDO_0004975","EFO_1000781","EFO_0000612","MONDO_0005148","MONDO_0005178"],"count":69},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and has 9 approved and 56 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL159659","canonicalSmiles":"CCC(=O)C(C[C@@H](C)N(C)C)(c1ccccc1)c1ccccc1","inchiKey":"USSIQXCVUWKGNF-QGZVFWFLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LEVOMETHADONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(-)-methadone","(6r)-methadone","(r)-methadone","D-(-)-methadone","L-methadone","L-polamivet","Levomethadone","Levothyl","Polamivet","R-(-)-methadone"],"crossReferences":{"drugbank":["DB13515"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL16","canonicalSmiles":"O=C1N=C(O)NC1(c1ccccc1)c1ccccc1","inchiKey":"CXOFVDLJLONNDW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENYTOIN","yearOfFirstApproval":1953,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Dilabid","Dilantin","Dilantin-125","Dilantin-30","Diphenylhydantoin","Hydantol","Phentytoin","Phenytoin"],"synonyms":["Diphenylhydantoin","Epamin","Lepitoin","NSC-8722","Phenytek","Phenytex","Phenytoin","Phenytoinum","SM-88 COMPONENT PHENYTOIN","Zentropil"],"crossReferences":{"DailyMed":["phenytoin","phenytoin%20sodium"],"PubChem":["11111069","11532994","124879886","124886706","144204412","144209497","144210601","170464785","17389903","26753026","26753027","26753028","50106148","56423134","85230999","90340679","90341165"],"TG-GATEs":["26"],"Wikipedia":["Phenytoin"],"drugbank":["DB00252"],"chEBI":["8107"]},"childChemblIds":["CHEMBL3274483","CHEMBL553532","CHEMBL4764504","CHEMBL3786353","CHEMBL1611"],"linkedTargets":{"rows":["ENSG00000185313","ENSG00000153253","ENSG00000183873","ENSG00000136546","ENSG00000144285","ENSG00000169432","ENSG00000168356","ENSG00000007314","ENSG00000136531","ENSG00000196876"],"count":10},"linkedDiseases":{"rows":["HP_0002069","EFO_0002618","MONDO_0005090","EFO_0007405","EFO_0002610","Orphanet_232","HP_0000726","HP_0001250","EFO_0000621","EFO_0000565","EFO_0009562","EFO_0000546","EFO_0000474","MONDO_0002050","EFO_1001996","EFO_0000574","EFO_0004272","MONDO_0004979","EFO_0005230"],"count":19},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for epilepsy and seizure and has 15 investigational indications."}
{"id":"CHEMBL1615784","canonicalSmiles":"CCOCCP(CCOCC)CCP(CCOCC)CCOCC","inchiKey":"QCWJONLQSHEGEJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TETROFOSMIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["P-53","P53","Tetrofosmin"],"crossReferences":{"drugbank":["DB11180"]},"description":"Small molecule drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL1623738","canonicalSmiles":"COc1ccc(CN(CCN(C)C)c2ncccn2)cc1","inchiKey":"GULNIHOSWFYMRN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"THONZYLAMINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Thonzylamine","Tonamil"],"crossReferences":{"Wikipedia":["Thonzylamine"],"drugbank":["DB11235"]},"childChemblIds":["CHEMBL1529802"],"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL1643","canonicalSmiles":"NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1","inchiKey":"IWUCXVSUMQZMFG-AFCXAGJDSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"RIBAVIRIN","yearOfFirstApproval":1985,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Copegus","Rebetol","Ribapak","Ribasphere","Ribavarin","Ribavirin","Ribofluranosyl Carboxamide","Tribavirin","Viramid","Virazid","Virazole"],"synonyms":["Cotronak","NSC-163039","Ribavirin","Ribavirin biopartners","Ribavirin mylan","Ribavirin teva","SCH 18908","SCH-18908","Tribavirin"],"crossReferences":{"DailyMed":["ribavirin"],"PubChem":["144203810","144208165","170464657","17389529","50105410","50105411","50105412","50105413","8139972","90341426"],"Wikipedia":["Ribavirin"],"drugbank":["DB00811"],"chEBI":["63580"]},"linkedTargets":{"rows":["ENSG00000106348"],"count":1},"linkedDiseases":{"rows":["MONDO_0007254","EFO_1001413","EFO_0007304","EFO_0007303","EFO_0007294","MONDO_0002050","EFO_0000544","Orphanet_68364","EFO_0006890","EFO_0000182","EFO_0004272","EFO_0007332","EFO_0003047","EFO_0007299","HP_0012115","EFO_0000694","EFO_0000616","MONDO_0600002","EFO_0001642","EFO_0007338","EFO_0000222","EFO_0004197","HP_0001873","EFO_0004239","EFO_0001422","EFO_0004220","EFO_0007306","MONDO_0100096","EFO_0000764","EFO_0001421","MONDO_0005147","EFO_0007328","EFO_0000763"],"count":33},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 20 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1683","canonicalSmiles":"CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C","inchiKey":"BMCQMVFGOVHVNG-TUFAYURCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HYDROCORTISONE BUTYRATE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Hydrocortisone butyrate","Locoid","Locoid c","Locoid crelo","Locoid lipocream"],"synonyms":["Cortisol 17-butyrate","Hydrocortisone 17-butyrate","Hydrocortisone butyrate","Hydrocortisone-17-butyrate","NSC-758433"],"crossReferences":{"DailyMed":["hydrocortisone%20butyrate"],"PubChem":["11533027","144204950","170465456","56422894"],"Wikipedia":["Hydrocortisone_17-butyrate"],"drugbank":["DB14540"],"chEBI":["31674"]},"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["EFO_1001034","EFO_1001494","EFO_0009462","EFO_1000764","EFO_0000701","EFO_0000274"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 approved and 1 investigational indication."}
{"id":"CHEMBL1695","canonicalSmiles":"Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C.Cl","inchiKey":"YUKARLAABCGMCN-PKLMIRHRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TIAGABINE HYDROCHLORIDE","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1027","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Gabitril","Tiagabine hydrochloride"],"synonyms":["ABBOTT-70569 HYDROCHLORIDE","ABBOTT-70569.1","ABBOTT-70569.HCL","ABBOTT-705691","ABT-569","Abbott-70569","Abbott-70569.1","NNC-05-0328","NNC-050328","NO-05-0328","NO-050328","Tiagabine hcl","Tiagabine hydrochloride"],"crossReferences":{"DailyMed":["tiagabine%20hydrochloride"],"PubChem":["144205798","170465153","49681547"],"chEBI":["85388"]},"linkedTargets":{"rows":["ENSG00000157103"],"count":1},"linkedDiseases":{"rows":["EFO_1001892","EFO_1001917","HP_0001250","EFO_0005230"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for seizure and has 2 investigational indications."}
{"id":"CHEMBL1743058","drugType":"Antibody","blackBoxWarning":false,"name":"PONEZUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PF-04360365","Ponezumab","RN-1219"],"linkedTargets":{"rows":["ENSG00000142192"],"count":1},"linkedDiseases":{"rows":["EFO_0006790","MONDO_0004975"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1796997","canonicalSmiles":"[He]","inchiKey":"SWQJXJOGLNCZEY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HELIUM","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["E-939","E939","Helium","Helium-4","INS NO.939","INS-939"],"crossReferences":{"drugbank":["DB09155"],"chEBI":["30217"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 2 investigational indications."}
{"id":"CHEMBL187709","canonicalSmiles":"CCN(CC)CCOc1ccc(C(O)(Cc2ccc(Cl)cc2)c2ccc(C)cc2)cc1","inchiKey":"SYHDSBBKRLVLFF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRIPARANOL","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["France"," United States"],"classes":["Dermatological toxicity"," Opthalmic toxicity"],"year":1962},"tradeNames":[],"synonyms":["NSC-65345","Triparanol"],"crossReferences":{"PubChem":["144205821","170466640","29217665","50111719"]},"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in France and  United States initially in 1962 due to Dermatological toxicity and  Opthalmic toxicity."}
{"id":"CHEMBL2095207","canonicalSmiles":"C[N+](C)([11CH3])CCO.[Cl-]","inchiKey":"SGMZJAMFUVOLNK-ULWFUOSBSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"CHOLINE C-11","yearOfFirstApproval":2012,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL282468","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Choline c-11"],"synonyms":["Choline (11c)","Choline c-11","Choline c-11 cation","Choline c-11 ion"],"crossReferences":{"drugbank":["DB09277"],"chEBI":["72321"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for prostate cancer and prostate adenocarcinoma."}
{"id":"CHEMBL2103837","canonicalSmiles":"O=C(O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1","inchiKey":"TXEIIPDJKFWEEC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TAFAMIDIS","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Vyndamax","Vyndaqel"],"synonyms":["FX-1005","FX-1006","FX1006","Tafamidis"],"crossReferences":{"DailyMed":["tafamidis","tafamidis%20meglumine"],"drugbank":["DB11644"],"chEBI":["78538"]},"childChemblIds":["CHEMBL2105675"],"linkedTargets":{"rows":["ENSG00000118271"],"count":1},"linkedDiseases":{"rows":["EFO_0009562","EFO_1001984","EFO_0000318","EFO_1001875","Orphanet_271861","Orphanet_85447","Orphanet_85443"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 3 investigational indications."}
{"id":"CHEMBL2104114","canonicalSmiles":"CN(CCOP(=O)(O)O)C(=N)N","inchiKey":"FOIPWTMKYXWFGC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CREATINOLFOSFATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cop","Creatinol o-phosphate","Creatinolfosfate"],"crossReferences":{"drugbank":["DB13071"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2104537","canonicalSmiles":"COc1cc(C(=O)OC(COCCC(C)C)CN2CCOCC2)cc(OC)c1OC","inchiKey":"YOKPRDAUBGOISU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMOPROXAN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["France"],"classes":["Dermatological toxicity"],"year":1970},"tradeNames":[],"synonyms":["Amoproxan","CERM 730","CERM-730"],"crossReferences":{"PubChem":["144206871"]},"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in France  in 1970 due to Dermatological toxicity."}
{"id":"CHEMBL2105318","canonicalSmiles":"C[C@]12CC[C@@H]3[C@H]4CCC(=O)C(O)=C4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1","inchiKey":"KHKDIUPVDIEHAH-KXLSUQFWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXABOLONE CIPIONATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["FI 5852","FI-5852","NSC-522767","Oxabolone cipionate"],"crossReferences":{"PubChem":["144206313"],"drugbank":["DB13185"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2105722","canonicalSmiles":"CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C","inchiKey":"KZUIYQJTUIACIG-YBZCJVABSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NOMEGESTROL","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Nomegestrol"],"crossReferences":{"drugbank":["DB11636"]},"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL2106119","canonicalSmiles":"O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2]","inchiKey":"NEEHYRZPVYRGPP-IYEMJOQQSA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"CALCIUM GLUCONATE","yearOfFirstApproval":2017,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Calcium gluconate in sodium chloride","Calglucon","H-f antidote"],"synonyms":["Calcarea gluconica","Calcii gluconas","Calcium di-gluconate","Calcium gluconate","Calcium gluconate anhydrous","Calcium gluconate, anhydrous","E-578","INS NO.578","INS-578","NSC-744619"],"crossReferences":{"DailyMed":["calcium%20gluconate"],"DrugCentral":["4348"],"drugbank":["DB11126"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for hypocalcemia and has 4 investigational indications."}
{"id":"CHEMBL2106780","canonicalSmiles":"Cc1ccc(S(=O)(=O)O)cc1.NCCO[N+](=O)[O-]","inchiKey":"HPPBBWMYZVALRK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ITRAMIN TOSYLATE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL609980","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Itramin tosilate","Itramin tosylate"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2107123","canonicalSmiles":"N[C@@H](CCC(=O)[O-])C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)[O-].[Na+].[Na+]","inchiKey":"GDLPAGOVHZLZEK-JBUFHSOLSA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"OGLUFANIDE DISODIUM","maximumClinicalTrialPhase":2,"parentId":"CHEMBL2111029","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Glufanide disodium","IM-862","IM862","Oglufanide disodium"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2107253","canonicalSmiles":"COc1cc([N-]S(=O)(=O)c2ccc(N)cc2)nc(OC)n1.[Na+]","inchiKey":"DQDZQHMCPDUUPC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULFADIMETHOXINE SODIUM","maximumClinicalTrialPhase":4,"parentId":"CHEMBL62193","hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"]},"tradeNames":[],"synonyms":["Di-methox","Sodium sulfadimethoxine","Sulfadimethoxine sodium","Sulfadimethoxine sodium salt"],"crossReferences":{"chEBI":["81722"]},"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in United States."}
{"id":"CHEMBL2107288","canonicalSmiles":"O=C(O)c1ccccc1O.OCCN(CCO)CCO","inchiKey":"UEVAMYPIMMOEFW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TROLAMINE SALICYLATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Neo heliopan ts","Neotan w","Tea-salicylate","Trolamine salicylate"],"crossReferences":{"DrugCentral":["4442"],"PubChem":["144208282"],"drugbank":["DB11079"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2108567","drugType":"Antibody","blackBoxWarning":false,"name":"TANEZUMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PF-04383119","PF-4383119","RN-624","RN624","Tanezumab"],"linkedTargets":{"rows":["ENSG00000134259"],"count":1},"linkedDiseases":{"rows":["EFO_1000783","MONDO_0041052","HP_0012532","EFO_0001065","EFO_1000786","EFO_0004616","HP_0003419","EFO_1000869","EFO_0003830","EFO_0000342","MONDO_0005178","EFO_0003843"],"count":12},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications."}
{"id":"CHEMBL2109648","drugType":"Antibody","blackBoxWarning":false,"name":"REGN-846","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["REGN-846","SAR302352"],"description":"Antibody drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2110686","canonicalSmiles":"CC(C)(CCCCOCCCCC(C)(C)C(=O)O)C(=O)O","inchiKey":"SDMBRCRVFFHJKR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GEMCABENE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Gemcabene"],"crossReferences":{"drugbank":["DB05123"]},"childChemblIds":["CHEMBL2105057"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2111088","canonicalSmiles":"COC(=O)Nc1nc2cc(Sc3ccc(NC(=O)[C@H](C)N)cc3)ccc2[nH]1","inchiKey":"GAOHLWCIAJNSEE-JTQLQIEISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DENIBULIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Denibulin"],"crossReferences":{"drugbank":["DB05932"]},"childChemblIds":["CHEMBL2107329"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2180604","canonicalSmiles":"Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1","inchiKey":"DZFZXPPHBWCXPQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TAK-593","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["TAK 593","TAK-593","Tak-593"],"crossReferences":{"drugbank":["DB13093"]},"linkedTargets":{"rows":["ENSG00000134853","ENSG00000128052","ENSG00000102755","ENSG00000037280","ENSG00000113721"],"count":5},"linkedDiseases":{"rows":["EFO_0000616"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2218917","canonicalSmiles":"CC1OC2(CS1)CN1CCC2CC1.Cl.O","inchiKey":"JKJRNPOQQPBPOV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEVIMELINE HYDROCHLORIDE","yearOfFirstApproval":2000,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL168815","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cevimeline","Cevimeline hydrochloride","Evoxac"],"synonyms":["AF-102B","AF102B","Cevimeline hcl","Cevimeline hydrochloride","Cevimeline hydrochloride hemihydrate","Cevimeline hydrochloride hydrate","FKS-508","SND-5008","SNI-2011","SNK-508","Saligren"],"crossReferences":{"DailyMed":["cevimeline%20hydrochloride"]},"linkedTargets":{"rows":["ENSG00000133019","ENSG00000168539"],"count":2},"linkedDiseases":{"rows":["EFO_0009869"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2000 and is indicated for xerostomia."}
{"id":"CHEMBL2251610","canonicalSmiles":"CCOC(=O)c1ccccc1O","inchiKey":"GYCKQBWUSACYIF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETHYL SALICYLATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144206317","144207003","170466844"],"drugbank":["DB15576"],"chEBI":["88839"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL230158","canonicalSmiles":"CCO[C@H](COc1ccc(C(F)(F)F)cc1)CSc1ccc(OCC(=O)O)c(C)c1","inchiKey":"JWHYSEDOYMYMNM-QGZVFWFLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SELADELPAR","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MBX-8025","Mbx-8025","RWJ-800025","Seladelpar"],"crossReferences":{"drugbank":["DB12390"]},"childChemblIds":["CHEMBL3989960"],"linkedTargets":{"rows":["ENSG00000112033"],"count":1},"linkedDiseases":{"rows":["EFO_0004268","MONDO_0021187","EFO_0001421","EFO_1001249","Orphanet_391665","EFO_1001486"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL230354","canonicalSmiles":"CC(=O)Nc1cccc(Nc2nc(Nc3ccccc3)n3ncc(C#N)c3n2)c1","inchiKey":"QVKXQLGRDOMAGC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL230354","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08362"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL23293","canonicalSmiles":"CC(C)=CCC/C(C)=C/CC/C(C)=C/CSc1ccccc1C(=O)O","inchiKey":"WUILNKCFCLNXOK-CFBAGHHKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SALIRASIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["FTS","Salirasib"],"crossReferences":{"PubChem":["11111197","50106301","50106302","520931","85231054"],"drugbank":["DB12681"]},"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL2357792","canonicalSmiles":"CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)c5ccccc5[C@]45C[C@@H](C2[C@H]5O)N3[C@@H]1O","inchiKey":"CJDRUOGAGYHKKD-HEFSZTOGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL2357792","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144204279"],"drugbank":["DB01426"],"chEBI":["28462"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL236720","canonicalSmiles":"COCc1cc(O)cc2c1O[C@@H](c1ccc(O)cc1)[C@H]1CC(F)(F)C[C@@H]21","inchiKey":"GPFRMIHXGMVMGF-BZSNNMDCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL236720","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07036"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL253978","canonicalSmiles":"Cc1scc2c1N(C(=O)CN1CCN(C)CC1)c1ccccc1NC2=O","inchiKey":"VSWPGAIWKHPTKX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TELENZEPINE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-758679","Telenzepine"],"crossReferences":{"PubChem":["104171244","11111843","11111844","11113930","11532931","144203825","170466639","26752083","90341323"],"Wikipedia":["Telenzepine"]},"childChemblIds":["CHEMBL1256762","CHEMBL1257109"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL256997","canonicalSmiles":"O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1","inchiKey":"OOUGLTULBSNHNF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ATALUREN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Ataluren","PTC-124","PTC124","Translarna"],"crossReferences":{"PubChem":["144206184","170466862","85852879","87334013","99460885"],"Wikipedia":["Ataluren"],"drugbank":["DB05016"]},"linkedTargets":{"rows":["ENSG00000148303","ENSG00000142937","ENSG00000171863","ENSG00000265681","ENSG00000116251","ENSG00000198755","ENSG00000147403","ENSG00000177954","ENSG00000142534","ENSG00000124614","ENSG00000100316","ENSG00000008988","ENSG00000149806","ENSG00000137154","ENSG00000161016","ENSG00000143947","ENSG00000167526","ENSG00000166441","ENSG00000089157","ENSG00000186468","ENSG00000130255","ENSG00000105372","ENSG00000172809","ENSG00000161970","ENSG00000171858","ENSG00000231500","ENSG00000164587","ENSG00000142676","ENSG00000145425","ENSG00000142541","ENSG00000071082","ENSG00000129824","ENSG00000213741","ENSG00000122406","ENSG00000108298","ENSG00000188846","ENSG00000136942","ENSG00000197958","ENSG00000105640","ENSG00000162244","ENSG00000170889","ENSG00000174444","ENSG00000174748","ENSG00000138326","ENSG00000137818","ENSG00000110700","ENSG00000083845","ENSG00000131469","ENSG00000122026","ENSG00000144713","ENSG00000198918","ENSG00000109475","ENSG00000168028","ENSG00000145592","ENSG00000147604","ENSG00000198242","ENSG00000108107","ENSG00000115268","ENSG00000114391","ENSG00000089009","ENSG00000063177","ENSG00000182774","ENSG00000198034","ENSG00000241343","ENSG00000182899","ENSG00000149273","ENSG00000163682","ENSG00000125691","ENSG00000233927","ENSG00000112306","ENSG00000134419","ENSG00000197756","ENSG00000118181","ENSG00000105193","ENSG00000140988","ENSG00000197728","ENSG00000229117","ENSG00000156482"],"count":78},"linkedDiseases":{"rows":["Orphanet_98896","Orphanet_77","EFO_0000474","Orphanet_98895","Orphanet_79062","Orphanet_98879","Orphanet_586","Orphanet_98878"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL260829","canonicalSmiles":"Cc1cccc(C)c1NC(=O)CN1CCCC1=O","inchiKey":"NGHTXZCKLWZPGK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NEFIRACETAM","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-759830","Nefiracetam"],"crossReferences":{"PubChem":["144207070","144209114","144213342","170466286","174007185","90340767"],"Wikipedia":["Nefiracetam"],"drugbank":["DB13082"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL28","canonicalSmiles":"O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12","inchiKey":"KZNIFHPLKGYRTM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"APIGENIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-83244"],"crossReferences":{"PubChem":["11110728","11110729","11113975","121464","124879148","124879150","124879152","124879154","124879155","144208740","144213201","17389511","174006549","26747161","26747162","26752115","26752116","46500336","50104771","50104772","50104773","50114379","50114380","85230903","90341029"],"Wikipedia":["Apigenin"],"drugbank":["DB07352"],"chEBI":["18388"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL284362","canonicalSmiles":"CCc1ccc(NC(=O)P(=O)(O)O)cc1","inchiKey":"KGNSYMGWPCEFDZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"[(4-Ethylphenyl)Amino]Carbonylphosphonic Acid","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["[(4-Ethylphenyl)Amino]Carbonylphosphonic Acid"],"crossReferences":{"drugbank":["DB03628"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL288470","canonicalSmiles":"Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C","inchiKey":"RMMXTBMQSGEXHJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMINOPYRINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom"," United States"," Germany"," France"],"classes":["Hematological toxicity"],"year":1970},"tradeNames":[],"synonyms":["4-dimethylaminoantipyrine","Amidazophene","Amidopyrazoline","Amidopyrine","Aminophenazone","Aminopyrine","Brufaneuxol","Dereuma","Febron","Itamidone","Mamallet a","NSC-4993","Netsusarin"],"crossReferences":{"PubChem":["104171274","11112141","144203884","144208742","144213147","170465863","17389912","56463351"],"Wikipedia":["Aminophenazone"],"drugbank":["DB01424"],"chEBI":["160246"]},"childChemblIds":["CHEMBL2104635"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for pain and fever. It was withdrawn in United Kingdom,  United States,  Germany and  France initially in 1970 due to Hematological toxicity."}
{"id":"CHEMBL291747","canonicalSmiles":"C[C@@H](O)[C@H](N)C(=O)O","inchiKey":"AYFVYJQAPQTCCC-GBXIJSLDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"THREONINE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["FEMA NO. 4710","L-threonine","NSC-16589","NSC-46701","Threonine"],"crossReferences":{"PubChem":["144205707","170465476"],"Wikipedia":["Threonine"],"drugbank":["DB00156"],"chEBI":["16857"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL293034","canonicalSmiles":"CN1C(=O)C(=O)c2cc(S(=O)(=O)N3CCC[C@H]3COc3ccccc3)ccc21","inchiKey":"PFAYCUAUBOGVDX-AWEZNQCLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL293034","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08213"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3039515","canonicalSmiles":"CCCCC1(CCCC)CN(c2ccccc2)c2cc(SC)c(OCC(=O)N[C@@H](C(=O)NCC(=O)O)c3ccccc3)cc2S(=O)(=O)C1","inchiKey":"XFLQIRAKKLNXRQ-UUWRZZSWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ELOBIXIBAT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["A-3309","A3309","AZD-7806","AZD7806","Elobixibat"],"crossReferences":{"drugbank":["DB12486"]},"linkedTargets":{"rows":["ENSG00000125255"],"count":1},"linkedDiseases":{"rows":["HP_0012450","EFO_1001249","HP_0002019","Orphanet_309005"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL313302","canonicalSmiles":"O=C1C=C(N2CC2)C(=O)C(N2CC2)=C1N1CC1","inchiKey":"PXSOHRWMIRDKMP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRIAZIQUONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BAYER 3231","BAYER-3231","NSC-29215","RIKER 601","RIKER-601","Teib","Triaziquone","Triethyleneiminobenzoquinone"],"crossReferences":{"drugbank":["DB13304"],"chEBI":["27090"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3137351","drugType":"Antibody","blackBoxWarning":false,"name":"ABRILUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AMG 181","AMG-181","Abrilumab","MEDI-7183","MEDI7183"],"linkedTargets":{"rows":["ENSG00000115232","ENSG00000139626"],"count":2},"linkedDiseases":{"rows":["EFO_0000729","EFO_0000384"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3301607","canonicalSmiles":"O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1","inchiKey":"RIJLVEAXPNLDTC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FILGOTINIB","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Filgotinib","G-146034","G146034","GLPG0634","GS-6034 FREE BASE","Glpg-0634"],"crossReferences":{"drugbank":["DB14845"]},"childChemblIds":["CHEMBL3301602","CHEMBL4298167"],"linkedTargets":{"rows":["ENSG00000162434"],"count":1},"linkedDiseases":{"rows":["EFO_0003834","EFO_0000729","EFO_0000685","EFO_1001231","EFO_0003086","EFO_0002690","EFO_0003898","EFO_0003778","EFO_0000540","EFO_0000384","EFO_0003767","EFO_0000699","EFO_0005629"],"count":13},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for immune system disease and has 11 investigational indications."}
{"id":"CHEMBL3301627","canonicalSmiles":"CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1.Cl.Cl","inchiKey":"VFRAXTZDILCRKY-OWRGXFNZSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"TENAPANOR HYDROCHLORIDE","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL3304485","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ibsrela"],"synonyms":["AZD-1722 HYDROCHLORIDE","AZD1722","AZD1722 hydrochloride","RDX-5791","RDX5791","Tenapanor dihydrochloride","Tenapanor hydrochloride"],"crossReferences":{"DailyMed":["tenapanor%20hydrochloride"]},"linkedTargets":{"rows":["ENSG00000066230"],"count":1},"linkedDiseases":{"rows":["EFO_0000555","EFO_0003884","HP_0002905","MONDO_0002203"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for constipation disorder and irritable bowel syndrome and has 2 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL3301669","canonicalSmiles":"CN[C@H]1C(=O)N[C@@H]2Cc3ccc(cc3)Oc3cc4cc(c3O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)Oc3ccc(cc3Cl)[C@@H](O)[C@@H]3NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@@H](NC2=O)c2cc(cc(O)c2Cl)Oc2cc1ccc2O)c1ccc(O)c(c1)-c1c(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)cc(O)cc1[C@@H](C(=O)NCCCN(C)C)NC3=O","inchiKey":"KGPGQDLTDHGEGT-SZUNQUCBSA-N","drugType":"Unknown","blackBoxWarning":false,"name":"DALBAVANCIN","yearOfFirstApproval":2014,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["A-A-1","BI-397","BI397","Dalbavancin","MDL 64,397","MDL-64397","VER-001","VER001","VERO001","Zeven"],"crossReferences":{"DailyMed":["dalbavancin%20hydrochloride"],"chEBI":["82721"]},"childChemblIds":["CHEMBL3301650"],"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for bacterial disease and infection and has 7 investigational indications."}
{"id":"CHEMBL3545114","drugType":"Small molecule","blackBoxWarning":false,"name":"KD3010","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Kd3010"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545153","drugType":"Small molecule","blackBoxWarning":false,"name":"DE-104","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["De-104"],"linkedTargets":{"rows":["ENSG00000134318","ENSG00000067900"],"count":2},"linkedDiseases":{"rows":["EFO_0004190","EFO_1001069"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3707298","canonicalSmiles":"[Mg+2].[O-][O-]","inchiKey":"SPAGIJMPHSUYSE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MAGNESIUM PEROXIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Drillox m","Magnesium dioxide","Magnesium perhydrol","Magnesium peroxide","Magnesium superoxol"],"crossReferences":{"drugbank":["DB13486"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3707355","drugType":"Small molecule","blackBoxWarning":false,"name":"AZD8108","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Azd8108"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3707375","canonicalSmiles":"CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F","inchiKey":"JVCPIJKPAKAIIP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMISELIMOD","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2240442","Amiselimod"],"childChemblIds":["CHEMBL3707374"],"linkedTargets":{"rows":["ENSG00000170989","ENSG00000180739","ENSG00000267534","ENSG00000213694","ENSG00000125910"],"count":5},"linkedDiseases":{"rows":["EFO_0000729","EFO_0002690","EFO_0000676","EFO_0003929","EFO_0000384","EFO_0003767"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL3707381","drugType":"Gene","blackBoxWarning":false,"name":"OFRANERGENE OBADENOVEC","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ofranergene obadenovec","VB-111"],"description":"Gene drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL3707404","drugType":"Antibody","blackBoxWarning":false,"name":"LUMRETUZUMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Lumretuzumab","RG-7116","RG7116","RO-5479599","RO5479599"],"linkedTargets":{"rows":["ENSG00000065361"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0007254","EFO_0003060"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL3707407","drugType":"Oligosaccharide","blackBoxWarning":false,"name":"CALCIUM ALGINATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Alginic acid calcium salt","Alginic acid, calcium salt","Calcium alginate","Calcium salt of alginic acid","E-404","FEMA NO. 2015","Flavikafine sf-d","Grindsted alginate fd 460","INS NO.404","INS-404"],"crossReferences":{"DrugCentral":["4431"]},"description":"Oligosaccharide drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL389433","canonicalSmiles":"Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1","inchiKey":"UGFHIPBXIWJXNA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LIAROZOLE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Liarozole","Liazal","R-75251"],"crossReferences":{"PubChem":["50125769"],"drugbank":["DB13066"]},"childChemblIds":["CHEMBL2105015","CHEMBL2105595"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3990032","drugType":"Antibody","blackBoxWarning":false,"name":"TELISOTUZUMAB VEDOTIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ABBV-399","ABT-399","Abbv 399","Abt-700-vcmmae","PR-1420682","Telisotuzumab vedotin"],"linkedTargets":{"rows":["ENSG00000261456","ENSG00000188229","ENSG00000104833","ENSG00000137267","ENSG00000258947","ENSG00000105976","ENSG00000101162","ENSG00000196230","ENSG00000137285","ENSG00000176014"],"count":10},"linkedDiseases":{"rows":["EFO_0000708","EFO_0003060","EFO_0000311"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL406863","canonicalSmiles":"NCC1(c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1","inchiKey":"QOZMRRGNAZNWDN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL406863","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08148"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL414357","canonicalSmiles":"CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O","inchiKey":"HTQBXNHDCUEHJF-XWLPCZSASA-N","drugType":"Protein","blackBoxWarning":true,"name":"EXENATIDE","yearOfFirstApproval":2005,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Bydureon","Bydureon bcise","Bydureon pen","Byetta"],"synonyms":["AC 2993","AC-002993","AC-2993","AC-2993A","AC-2993LAR","AC002993","AC2993","AC2993A","DA-3091","EXENDIN-4","Exenatide","Exenatide Synthetic","Exenatide synthetic","Exendin 4","ITCA-650","LY-2148568","LY2148568"],"crossReferences":{"DailyMed":["exenatide%20synthetic"]},"linkedTargets":{"rows":["ENSG00000112164"],"count":1},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0004566","EFO_0002610","EFO_0003095","EFO_0000401","HP_0001824","HP_0000083","EFO_0004593","MONDO_0005180","EFO_0000712","MONDO_0015183","MONDO_0007079","EFO_0000400","EFO_0002546","EFO_0007318","EFO_0004319","HP_0002140","EFO_0001074","EFO_0001645","EFO_0010445","EFO_0001073","EFO_0000660","EFO_1001050","EFO_1001121","MONDO_0005147","HP_0003074","EFO_0008583","EFO_0000612","MONDO_0043510","MONDO_0005148","EFO_0005411"],"count":31},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 20 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL415049","canonicalSmiles":"CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O","inchiKey":"GBJVVSCPOBPEIT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BARASERTIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZD 1152","AZD-1152","AZD1152","Azd-1152","Barasertib","Barasertib (who-dd)"],"crossReferences":{"PubChem":["103905346"],"drugbank":["DB11747"]},"linkedTargets":{"rows":["ENSG00000178999"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000574","EFO_0000222","MONDO_0004643"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL42","canonicalSmiles":"CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1","inchiKey":"QZUDBNBUXVUHMW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"CLOZAPINE","yearOfFirstApproval":1989,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Clozapine","Clozaril","Fazaclo","Fazaclo odt","Versacloz","Zaponex"],"synonyms":["Clozapine","Clozapine (caraco)","Clozapine (clozaril)","Clozapine (fazaclo)","Clozapine (ivax)","Clozapine (mylan)","Clozapine (teva)","Clozapine (udl)","Clozapine (versacloz)","Clozapine resolution mixture","HF 1854","HF-1854","Leponex","NSC-757429"],"crossReferences":{"DailyMed":["clozapine"],"PubChem":["104171134","11110967","11110968","11113341","124879684","124879686","124879688","124879690","124879691","144203664","170464853","26747001","26751524","50104084","50104086","56422144","85230974","855811","90341777"],"Wikipedia":["Clozapine"],"drugbank":["DB00363"],"chEBI":["3766"]},"childChemblIds":["CHEMBL538973"],"linkedTargets":{"rows":["ENSG00000149295","ENSG00000102468"],"count":2},"linkedDiseases":{"rows":["EFO_0000195","MONDO_0005090","EFO_0000289","EFO_0004262","MONDO_0002050","HP_0000726","EFO_0000677","EFO_0005407","EFO_0003847","EFO_0005230","EFO_0005411","EFO_0003852"],"count":12},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL4205783","canonicalSmiles":"Clc1ccc(-c2nn(Cc3ccccc3)c3c2CCNCC3)cc1","inchiKey":"UKJPMZGILXATGT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"JNJ-18038683","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"childChemblIds":["CHEMBL4297293"],"linkedTargets":{"rows":["ENSG00000148680"],"count":1},"linkedDiseases":{"rows":["EFO_0000289","MONDO_0002009"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297208","drugType":"Small molecule","blackBoxWarning":false,"name":"TRIPLATIN TETRANITRATE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BBR 3464","BBR-3464","BBR3464","Bbr 3464","Triplatin tetranitrate"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297245","drugType":"Antibody","blackBoxWarning":false,"name":"DONANEMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Donanemab","LY 3002813","LY-3002813","LY3002813"],"linkedTargets":{"rows":["ENSG00000142192"],"count":1},"linkedDiseases":{"rows":["MONDO_0004975"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4297399","canonicalSmiles":"O=C(Nc1ncc(SCCN2CCCC2)s1)[C@]1(c2ccc(S(=O)(=O)C3CC3)cc2)C[C@H]1C1CCCCC1","inchiKey":"QIIVJLHCZUTGSD-CUBQBAPOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LY-2608204","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LY2608204","Ly-2608204","Ly2608204"],"crossReferences":{"drugbank":["DB12284"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297765","drugType":"Unknown","blackBoxWarning":false,"name":"HT-2157","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["HT-2157","Ht-2157","SNAP-37889"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297852","drugType":"Protein","blackBoxWarning":false,"name":"CENEGERMIN","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Oxervate"],"synonyms":["Cenegermin","Cenegermin-bkbj"],"crossReferences":{"DailyMed":["cenegermin-bkbj"]},"linkedTargets":{"rows":["ENSG00000140538","ENSG00000148053","ENSG00000198400"],"count":3},"linkedDiseases":{"rows":["EFO_0003966","EFO_0009449","EFO_1000906"],"count":3},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for keratitis and eye disease."}
{"id":"CHEMBL4297877","drugType":"Antibody","blackBoxWarning":false,"name":"BALSTILIMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AGEN-2034","AGEN2034","Agen2034","Balstilimab"],"linkedTargets":{"rows":["ENSG00000188389"],"count":1},"linkedDiseases":{"rows":["EFO_1000026","EFO_0000294","EFO_0000616","EFO_0003968","MONDO_0002974","EFO_1001968","EFO_0000311"],"count":7},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL4297918","drugType":"Antibody","blackBoxWarning":false,"name":"SETRUSUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BPS-804","BPS804","Bps804","MOR05813","Setrusumab"],"linkedTargets":{"rows":["ENSG00000167941"],"count":1},"linkedDiseases":{"rows":["EFO_0003086","Orphanet_436","Orphanet_666"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4298074","drugType":"Unknown","blackBoxWarning":false,"name":"POTASSIUM PHOSPHATE, UNSPECIFIED FORM","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Potassium (as phosphate)","Potassium phosphate","Potassium phosphate, unspecified form"],"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4298183","drugType":"Antibody","blackBoxWarning":false,"name":"ATOLTIVIMAB","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Atoltivimab","Atoltivimab-ebgn","REGN3470","Regn-3470"],"description":"Antibody drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for ebola hemorrhagic fever."}
{"id":"CHEMBL43185","canonicalSmiles":"O=C(/C=C/C=C/c1ccc2c(c1)OCO2)N1CCCCC1","inchiKey":"MXXWOMGUGJBKIW-YPCIICBESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PIPERINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bioperine","FEMA NO. 2909","NSC-21727","Piperine"],"crossReferences":{"PubChem":["144209188","144213063","26748436","26753730","56463241"],"Wikipedia":["Piperine"],"drugbank":["DB12582"],"chEBI":["28821"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL437747","canonicalSmiles":"CCCn1c(C2CCNCC2)nc(-c2ccc(Cl)c(Cl)c2)c1-c1ccnc(NC2CCCCC2)n1","inchiKey":"UQFRSHRWRKYNDE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL437747","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["103905437"],"drugbank":["DB02388"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL440283","canonicalSmiles":"C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC[C@@H]2O","inchiKey":"QADHLRWLCPCEKT-LOVVWNRFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ANDROSTENEDIOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Androstenediol"],"crossReferences":{"PubChem":["144206048","170465858","50112747"],"Wikipedia":["5-Androstenediol"],"drugbank":["DB01524"],"chEBI":["2710"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL443684","canonicalSmiles":"CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1","inchiKey":"JLYAXFNOILIKPP-KXQOOQHDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NAVITOCLAX","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["A-855071.0","ABT-263","Navitoclax"],"crossReferences":{"drugbank":["DB12340"]},"childChemblIds":["CHEMBL2105690"],"linkedTargets":{"rows":["ENSG00000171552","ENSG00000258643","ENSG00000171791","ENSG00000129473"],"count":4},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0000873","EFO_0000220","EFO_0001642","MONDO_0008170","EFO_0000403","EFO_0000222","MONDO_0008315","EFO_0003060","EFO_0000311","EFO_0002430","EFO_0004251","EFO_0000095","EFO_0000702"],"count":14},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications."}
{"id":"CHEMBL445162","canonicalSmiles":"CS(=O)(=O)c1cccc(Nc2nccc(Nc3c(Cl)ccc4c3OCO4)n2)c1","inchiKey":"QTFCKBFCXDAZIU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL445162","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07253"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL456","canonicalSmiles":"C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl","inchiKey":"AVOLMBLBETYQHX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETHACRYNIC ACID","yearOfFirstApproval":1967,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Edecrin","Ethacrynic acid","Hydromedin","Reomax"],"synonyms":["Etacrynic acid","Ethacrynate","Ethacrynic acid","MK-595","NSC-624008","NSC-85791"],"crossReferences":{"DailyMed":["ethacrynate%20sodium","ethacrynic%20acid"],"PubChem":["104171276","11112144","122995","124881977","124881979","144203886","144208300","170465426","17389016","26746983","26746984","50100377","855762","92763949"],"Wikipedia":["Etacrynic_acid"],"drugbank":["DB00903"],"chEBI":["4876"]},"childChemblIds":["CHEMBL1200487"],"linkedTargets":{"rows":["ENSG00000074803"],"count":1},"linkedDiseases":{"rows":["EFO_0009690","EFO_0001422","EFO_1001134","EFO_0004255","EFO_0000373","EFO_0000319","EFO_0000516","MONDO_0001187"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 6 approved and 2 investigational indications."}
{"id":"CHEMBL4594234","drugType":"Small molecule","blackBoxWarning":false,"name":"FIRTECAN PEGOL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["EZN-2208","Ezn-2208","Firtecan pegol","Peg-sn38"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4594441","canonicalSmiles":"COc1cc(Nc2ncc(C)c(Nc3ccc4oc(=O)[nH]c4c3)n2)cc(C)c1F","inchiKey":"OYFMQDVLFYKOPZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IFIDANCITINIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["A-301","ATI-502","Ati-502","Ifidancitinib"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4594501","drugType":"Unknown","blackBoxWarning":false,"name":"TAK-137","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Tak-137"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4594557","drugType":"Unknown","blackBoxWarning":false,"name":"EFTILAGIMOD ALFA","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Eftilagimod alfa","IMP321","Immufact","Imp321"],"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4594574","drugType":"Unknown","blackBoxWarning":false,"name":"LY-3415244","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ly-3415244","Ly3415244"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4650310","canonicalSmiles":"O=c1ccc2ccc(O[C@H]3C[C@@H]4CC[C@H](C3)N4)cc2o1","inchiKey":"PGUDASZQLOAZRX-DABQJJPHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IP-2018","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["IP-2018","IP2018","Ip-2018","Ip2018"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4650446","drugType":"Unknown","blackBoxWarning":false,"name":"AZD-7648","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZD-7648","AZD7648","Azd-7648","Azd7648"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4650522","drugType":"Unknown","blackBoxWarning":false,"name":"ORN-0829 HYDRATE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ORN-0829 HYDRATE","ORN0829 HYDRATE","Orn-0829 hydrate","Ts-142"],"linkedTargets":{"rows":["ENSG00000137252","ENSG00000121764"],"count":2},"linkedDiseases":{"rows":["EFO_0003918","EFO_0004698"],"count":2},"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL479032","canonicalSmiles":"O=c1ccc(Cc2ccc(Cl)c(Oc3ccccc3)c2F)n[nH]1","inchiKey":"NOVPOXGMADEKPP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL479032","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08379"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL483","canonicalSmiles":"C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O","inchiKey":"SGOIRFVFHAKUTI-ZCFIWIBFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TENOFOVIR","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Atripla","GS-1275","PMP-A","Tenofovir","Truvada"],"crossReferences":{"Wikipedia":["Tenofovir"],"drugbank":["DB14126"],"chEBI":["63625"]},"childChemblIds":["CHEMBL3989702"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications."}
{"id":"CHEMBL488280","canonicalSmiles":"CCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-]","inchiKey":"YZZCJYJBCUJISI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PROPATYL NITRATE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Etrynit"],"synonyms":["ETT-N","ETTN","Propatyl nitrate","Propatylnitrate","WIN 9317","WIN-9317"],"crossReferences":{"Wikipedia":["Propatylnitrate"],"drugbank":["DB13255"]},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL515","canonicalSmiles":"O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1","inchiKey":"JCKYGMPEJWAADB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"CHLORAMBUCIL","yearOfFirstApproval":1957,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Leukeran"],"synonyms":["Ambochlorin","CB-1348","Chlorambucil","Chlorambucilum","Chlorbutin","Ecloril","Lympholysin","NCI-3088","NSC-3088"],"crossReferences":{"DailyMed":["chlorambucil"],"PubChem":["104171121","11110896","11110897","124879524","124879525","144203647","144208588","144213313","170464770","17389986","174007440","26747015","50104127","50126363","56422109","69624","85230952","855863","90341264"],"Wikipedia":["Chlorambucil"],"drugbank":["DB00291"],"chEBI":["28830"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 3 approved and 9 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL539163","canonicalSmiles":"Cn1c(C#N)ccc1-c1ccc2c(c1)C(C)(C)OC(=S)N2","inchiKey":"PYVFWTPEBMRKSR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TANAPROGET","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSP-989","Tanaproget"],"crossReferences":{"drugbank":["DB04787"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL550","canonicalSmiles":"CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C","inchiKey":"QCHFTSOMWOSFHM-WPRPVWTQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PILOCARPINE","yearOfFirstApproval":1974,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ocusert pilo","Ocusert pilo-20","Ocusert pilo-40"],"synonyms":["Ocucarpine","Pilocarpine","Pilocarpinum","Pilocarpol","Pilokarpin","Spersacarpine","Syncarpine"],"crossReferences":{"DailyMed":["pilocarpine%20hydrochloride"],"PubChem":["11113352","170464845","26751548","50104139","90340957","90341610"],"Wikipedia":["Pilocarpine"],"drugbank":["DB01085"],"chEBI":["8207"]},"childChemblIds":["CHEMBL2139597","CHEMBL1200330","CHEMBL1213136"],"linkedTargets":{"rows":["ENSG00000133019","ENSG00000168539"],"count":2},"linkedDiseases":{"rows":["MONDO_0001330","EFO_0004190","EFO_1001069","EFO_0006859","EFO_1000906","MONDO_0001744","HP_0000020","EFO_1001914","EFO_0000516","EFO_0000699","HP_0000616","EFO_0009869"],"count":12},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 7 approved and 3 investigational indications."}
{"id":"CHEMBL570680","canonicalSmiles":"CC(C)(N)CNC(=O)C[C@H]1CC[C@]2(CC1)OO[C@]1(O2)C2CC3CC(C2)CC1C3.Cc1ccc(S(=O)(=O)O)cc1","inchiKey":"ZNEZSLAXOUSCDT-KDJJSNTDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ARTEROLANE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL404431","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Arterolane","OZ 277","OZ-277","RBX-11160","RBX11160"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL573352","canonicalSmiles":"C#C[C@@]1(O)[C@@H](CO)O[C@@H](n2ccc(N)nc2=O)[C@@H]1O","inchiKey":"JFIWEPHGRUDAJN-DYUFWOLASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TAS-106","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2'-C-Ethynylcytidine","3'-C-Ethynylcytidine","Tas 106","Tas-106"],"crossReferences":{"drugbank":["DB06656"]},"linkedTargets":{"rows":["ENSG00000148606","ENSG00000181222","ENSG00000068654"],"count":3},"linkedDiseases":{"rows":["EFO_0006859","EFO_0000311"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL583969","canonicalSmiles":"Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)CP(=O)(O)O)[C@@H](O)[C@H]1O","inchiKey":"OLCWZBFDIYXLAA-IOSLPCCCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHOSPHOMETHYLPHOSPHONIC ACID ADENOSYL ESTER","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["11532930","26756681"],"drugbank":["DB03148"],"chEBI":["40730"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL66412","canonicalSmiles":"CN(C(=O)Oc1ccc(Cl)cc1)[C@H]1CC[C@H](c2ccc(CN3CCCCC3)cc2)CC1","inchiKey":"AMKFOVYTEUFMCU-HCGLCNNCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL66412","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03748"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL723","canonicalSmiles":"COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12","inchiKey":"OGHNVEJMJSYVRP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CARVEDILOL","yearOfFirstApproval":1995,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Carvedilol","Coreg","Coreg CR","Eucardic 12.5","Eucardic 25","Eucardic 3.125","Eucardic 6.25"],"synonyms":["BM 14.190","BM-14-190","BM-14.190","BM-14190","C07AG02","Carvedilol","Coronis","DQ-2466","Dilatrend","Dimitone","Eucardic","Korvasan","Kredex","NSC-758694","SKF-105517","Talliton"],"crossReferences":{"DailyMed":["carvedilol","carvedilol%20phosphate"],"PubChem":["26719722","26719723","50112972","50112973","90341342"],"Wikipedia":["Carvedilol"],"drugbank":["DB01136"],"chEBI":["3441"]},"childChemblIds":["CHEMBL1201167","CHEMBL1437006"],"linkedTargets":{"rows":["ENSG00000169252","ENSG00000171873","ENSG00000170214","ENSG00000120907","ENSG00000043591","ENSG00000188778"],"count":6},"linkedDiseases":{"rows":["EFO_0003086","EFO_0001361","EFO_0002610","Orphanet_98895","EFO_0000275","MONDO_0007254","EFO_0003768","EFO_0000373","EFO_0009094","EFO_0003913","EFO_0003914","EFO_0000474","EFO_0008585","EFO_0003144","EFO_0004289","EFO_0000400","EFO_0000407","EFO_0008586","MONDO_0005149","HP_0003124","EFO_0001645","EFO_0000222","EFO_0001358","EFO_0000319","EFO_0000666","EFO_0001073","MONDO_0008315","EFO_0000537","EFO_0000311","Orphanet_98896","MP_0001914","EFO_0003896","HP_0012664","EFO_0001422","MONDO_0001134","MONDO_0004975","EFO_0000574","EFO_0008583","EFO_0009545","EFO_0000612","EFO_0001378","EFO_0000341","HP_0001943","MONDO_0005148","EFO_0000519","HP_0012594","EFO_0005672","EFO_0004264"],"count":48},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 5 approved and 27 investigational indications."}
{"id":"CHEMBL74632","canonicalSmiles":"CO[C@@]1(NC(=O)C(C(=O)O)c2ccc(O)cc2)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CO[C@@H]21","inchiKey":"JWCSIUVGFCSJCK-CAVRMKNVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MOXALACTAM","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Latamoxef","Moxalactam","Moxam"],"crossReferences":{"Wikipedia":["Latamoxef"],"drugbank":["DB04570"],"chEBI":["599928"]},"childChemblIds":["CHEMBL1200357"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for bacterial disease."}
{"id":"CHEMBL77622","canonicalSmiles":"Oc1ccc(CCNCCCCCCNCCc2ccccc2)cc1O","inchiKey":"RYBJORHCUPVNMB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DOPEXAMINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Dopexamine","FPL 60278","FPL-60278"],"crossReferences":{"PubChem":["124896575","144206582","170466408"],"Wikipedia":["Dopexamine"],"drugbank":["DB12313"]},"childChemblIds":["CHEMBL3989581"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 1 investigational indication."}
{"id":"CHEMBL8","canonicalSmiles":"O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O","inchiKey":"MYSWGUAQZAJSOK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"CIPROFLOXACIN","yearOfFirstApproval":1987,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cetraxal","Ciloxan","Cipro","Ciprobay","Ciprofloxacin","Otiprio","Velmonit"],"synonyms":["BAY O 9867 FREE BASE","BAY Q 3939","BAY-O-9867 FREE BASE","BAY-Q-3939","BAYQ3939","Ciloxan","Ciprofloxacin","Ciprofloxacinum","NSC-758467"],"crossReferences":{"DailyMed":["ciprofloxacin","ciprofloxacin%20hydrochloride"],"PubChem":["11112875","124882697","174007333","26748814"],"TG-GATEs":["50"],"Wikipedia":["Ciprofloxacin"],"drugbank":["DB00537"],"chEBI":["100241"]},"childChemblIds":["CHEMBL3764828","CHEMBL4303345","CHEMBL1077975","CHEMBL1202"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 12 approved and 41 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL833","canonicalSmiles":"Clc1ccccc1CN1CCc2sccc2C1","inchiKey":"PHWBOXQYWZNQIN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"TICLOPIDINE","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Ticlopidin-puren","Ticlopidine"],"crossReferences":{"DailyMed":["ticlopidine%20hydrochloride"],"PubChem":["104171328","11112786","124882626","144204209","170464698","26751617","50085878"],"TG-GATEs":["146"],"Wikipedia":["Ticlopidine"],"drugbank":["DB00208"],"chEBI":["9588"]},"childChemblIds":["CHEMBL1717"],"linkedTargets":{"rows":["ENSG00000169313"],"count":1},"linkedDiseases":{"rows":["MONDO_0000831","EFO_0000712","EFO_0001645","MONDO_0002679","EFO_1000883","HP_0004419","EFO_0004265","EFO_0002615"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL96741","canonicalSmiles":"Fc1ccc(-c2ncn(CC3CC3)c2-c2ccncc2)cc1","inchiKey":"ROKOFZNQCIIJMI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SB-216995","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SB-216995"],"crossReferences":{"drugbank":["DB08522"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
